about
A randomized, placebo-controlled trial of latrepirdine in Huntington disease.The potential of hematopoietic growth factors for treatment of Alzheimer's disease: a mini-reviewApoptosis in cultured hNT neurons.Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice.Vitamin A metabolite, all-trans-retinoic acid, mediates alternative splicing of protein kinase C deltaVIII (PKCdeltaVIII) isoform via splicing factor SC35.A double-blind evaluation of ciladopa in Parkinson's disease.Combination therapy of human umbilical cord blood cells and granulocyte colony stimulating factor reduces histopathological and motor impairments in an experimental model of chronic traumatic brain injury.Medical marijuana in neurology.Neural cells derived from adult bone marrow and umbilical cord blood.Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice.Quantitative analysis of tremors in welders.Do hematopoietic cells exposed to a neurogenic environment mimic properties of endogenous neural precursors?Brain as the Sea of Marrow.Evaluation of an α synuclein sensitized dendritic cell based vaccine in a transgenic mouse model of Parkinson diseaseStem cells from umbilical cord blood.Granulocyte colony-stimulating factor promotes behavioral recovery in a mouse model of traumatic brain injury.Effects of environmental enrichment and physical activity on neurogenesis in transgenic PS1/APP mice.Long-term cultured human umbilical cord neural-like cells transplanted into the striatum of NOD SCID mice.Green fluorescent protein bone marrow cells express hematopoietic and neural antigens in culture and migrate within the neonatal rat brain.Hyperkinetic movement disorders associated with HIV and other viral infections.Expression of neural markers in human umbilical cord blood.Neurologic Complications of Psychomotor Stimulant Abuse.A case of post-traumatic tic disorder.Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation.Hippocampal neurogenesis and the brain repair response to brief stereotaxic insertion of a microneedle.Can low level exposure to ochratoxin-A cause parkinsonism?Examining Huntington's disease patient and informant concordance on frontally mediated behaviors.Cannabinoids for the Treatment of Movement Disorders.Medication development of ibogaine as a pharmacotherapy for drug dependence.Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice.Effects of an Inhibitor of Monocyte Recruitment on Recovery from Traumatic Brain Injury in Mice Treated with Granulocyte Colony-Stimulating Factor.1-Methyl-4-phenylpyridinium (MPP+) increases oxidation of cytochrome-b in rat striatal slices.GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice.High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.Effects of MDMA ("ecstasy") during adolescence on place conditioning and hippocampal neurogenesis.Strain-specific differences in the expression and activity of Ogg1 in the CNS.Sleep disorders and sleep effect in Parkinson's disease.Effects of melanin and manganese on DNA damage and repair in PC12-derived neurons.Well-being of family caregivers of persons with late-stage Huntington's disease: lessons in stress and coping.The role of mitochondrial DNA in Huntington's disease.
P50
Q30411257-940C1E7B-BE8E-4788-8444-42BFF7B9AF85Q30855096-EC61CCA9-BE3B-479C-94D2-84786D282E3DQ33181854-755B7EC4-3423-4F00-9A9B-865A1A45F879Q34020814-E59967DE-F655-4BE3-AF80-46F2E7406D6DQ34074258-09EE6D49-D48E-4E0F-B1F1-9FE296CE1799Q34174677-B0506AAA-850D-48FB-8B13-8649675E5781Q34409696-A6B3F731-9BC0-44CA-8AC5-B00499381646Q34449698-2B965D54-300D-455B-9F7A-F5779F1CD28CQ34805868-AD577058-794F-4B2C-8F45-800E0924E7FDQ34985230-CA24A96A-E887-4233-870B-E233C5011EFBQ35024762-4F40E30E-5C70-4D42-B9C2-55FF1F731800Q35225233-3EA4A35C-87FD-4B90-AF04-60FC0B4BEE1DQ35592810-D5A900BC-1564-4251-A1F8-CE1E8E6D1BF6Q35887768-52B4072B-AFE4-40F0-BA1C-07217571B18EQ36661729-1997046A-1DD8-4E8C-ABCA-CEC3AFC26C3CQ36723127-11D087EB-CD49-4A34-812B-B7DB1A0188D7Q37097609-57AD6C57-144B-40CB-B952-452246D2F025Q37186930-54A6BC10-DF5D-458A-A2D8-8FF750731B20Q37289249-CDA04968-6727-4F08-95E6-65B0FB1A8C7AQ37865655-B59F920A-57BD-4AFE-B017-04C709D45A89Q38297540-9B5DEA3D-3BC3-46B8-8EC7-9E7F520E7364Q38526702-38B35058-AF1D-4ACE-A940-8F057B967C5AQ38715272-355E8716-8ED1-4953-87A4-69DD60409541Q39247268-325C1104-8861-48A1-AB71-A9C529518AF4Q39306350-08C2CA00-9488-4CBA-B627-CE1462464D01Q39433481-901532C1-54F9-4FB8-BFCD-D177F6AA9FA3Q40582237-4811ACB9-A9BB-42E9-9125-8BD93B5F2929Q40701861-91FE915E-C027-4262-A869-708EF12EE491Q40850975-0CEA2EF2-5B36-48C6-BDC9-63830CD17A13Q41165776-B3D99E9E-7544-4C9B-8F19-DA939356CFDDQ41181881-BDC0F63D-257D-4EB5-B998-F061958A1F38Q41422478-785589A2-31C0-48DF-B6C0-4EFE8836BCFBQ41611744-38F777C0-2D75-4214-8DE2-4B6C6EF09149Q42555195-67A1D828-7CBA-4D16-AB9F-94DA75FF9DE5Q43237122-885C3AEC-9B16-4DED-861C-24782CA15296Q44400771-50B5598C-D9B3-46DD-89BF-35479BD80A9AQ44474344-71DA8CC5-09AD-4167-A9EE-6847149A3B2BQ44842943-EA3E0D03-D9F0-4426-AC6B-3A9508177F34Q45293678-70F607A1-2471-433D-8600-76D7129F8E10Q45295958-9A4230D3-1049-439D-A8F2-663AB6B4572F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Juan Sanchez-Ramos
@ast
Juan Sanchez-Ramos
@en
Juan Sanchez-Ramos
@es
Juan Sanchez-Ramos
@nl
Juan Sanchez-Ramos
@sl
type
label
Juan Sanchez-Ramos
@ast
Juan Sanchez-Ramos
@en
Juan Sanchez-Ramos
@es
Juan Sanchez-Ramos
@nl
Juan Sanchez-Ramos
@sl
altLabel
Sanchez-Ramos J
@en
Zeno
@en
prefLabel
Juan Sanchez-Ramos
@ast
Juan Sanchez-Ramos
@en
Juan Sanchez-Ramos
@es
Juan Sanchez-Ramos
@nl
Juan Sanchez-Ramos
@sl
P1053
A-1188-2009
P106
P1153
7006667139
P21
P31
P3829
P4012
P496
0000-0002-3391-7857